Addex Therapeutics Valuation
| ADXN Stock | CHF 0.05 0.0002 0.41% |
Addex Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Addex Therapeutics from analyzing the firm fundamentals such as return on equity of -0.73, and Operating Margin of (14.04) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Addex Therapeutics' valuation include:
Price Book 1.2306 | Enterprise Value | Enterprise Value Ebitda (0.70) | Price Sales 45.1339 | Enterprise Value Revenue 165.7063 |
Overvalued
Today
Please note that Addex Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Addex Therapeutics is based on 3 months time horizon. Increasing Addex Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Addex stock is determined by what a typical buyer is willing to pay for full or partial control of Addex Therapeutics. Since Addex Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Addex Stock. However, Addex Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.048 | Real 0.043 | Hype 0.05 | Naive 0.0482 |
The intrinsic value of Addex Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Addex Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Addex Therapeutics helps investors to forecast how Addex stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Addex Therapeutics more accurately as focusing exclusively on Addex Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Addex Therapeutics' intrinsic value based on its ongoing forecasts of Addex Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Addex Therapeutics' closest peers.
Addex Therapeutics Cash |
|
Addex Therapeutics Total Value Analysis
Addex Therapeutics is presently anticipated to have takeover price of 5.18 M with market capitalization of 7.16 M, debt of 41.99 K, and cash on hands of 20.48 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Addex Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.18 M | 7.16 M | 41.99 K | 20.48 M |
Addex Therapeutics Investor Information
The company has price-to-book (P/B) ratio of 1.23. Some equities with similar Price to Book (P/B) outperform the market in the long run. Addex Therapeutics recorded a loss per share of 0.06. The entity last dividend was issued on the 26th of July 2022. Based on the key indicators related to Addex Therapeutics' liquidity, profitability, solvency, and operating efficiency, Addex Therapeutics is performing exceptionally good at this time. It has a great odds to report excellent financial results in March.Addex Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Addex Therapeutics has an asset utilization ratio of 3.84 percent. This indicates that the Company is making ₣0.0384 for each dollar of assets. An increasing asset utilization means that Addex Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Addex Therapeutics Profitability Analysis
Based on Addex Therapeutics' profitability indicators, Addex Therapeutics' profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess Addex Therapeutics' ability to earn profits and add value for shareholders.Net Income | First Reported 2012-09-30 | Previous Quarter -1.8 M | Current Value -1.6 M | Quarterly Volatility 2.9 M |
For Addex Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Addex Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Addex Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Addex Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Addex Therapeutics over time as well as its relative position and ranking within its peers.
Addex Therapeutics Earnings per Share Projection vs Actual
By analyzing Addex Therapeutics' earnings estimates, investors can diagnose different trends across Addex Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Addex Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Addex Therapeutics Ownership Allocation
Addex Therapeutics holds a total of 147.84 Million outstanding shares. Addex Therapeutics shows 6.06 percent of its outstanding shares held by insiders and 1.18 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Addex Therapeutics Profitability Analysis
The company reported the revenue of 410.04 K. Net Loss for the year was (4.91 M) with loss before overhead, payroll, taxes, and interest of (525.65 K).About Addex Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Addex Therapeutics. We calculate exposure to Addex Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Addex Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -399.8 K | -419.8 K | |
| Pretax Profit Margin | (10.78) | (11.31) | |
| Operating Profit Margin | (6.05) | (6.35) | |
| Net Profit Margin | 15.49 | 16.26 | |
| Gross Profit Margin | (0.98) | (1.02) |
Additional Tools for Addex Stock Analysis
When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.